Cargando…

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation

Tacrolimus (Tac) is a profoundly effective immunosuppressant that reduces the risk of rejection after solid organ transplantation. However, its use is hampered by its narrow therapeutic window along with its highly variable pharmacological (pharmacokinetic [PK] and pharmacodynamic [PD]) profile. Par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woillard, Jean-Baptiste, Mourad, Michel, Neely, Michael, Capron, Arnaud, van Schaik, Ron H., van Gelder, Teun, Lloberas, Nuria, Hesselink, Dennis A., Marquet, Pierre, Haufroid, Vincent, Elens, Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462973/ https://www.ncbi.nlm.nih.gov/pubmed/28642710 http://dx.doi.org/10.3389/fphar.2017.00358

Ejemplares similares

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
por: Andrews, L. M., et al.
Publicado: (2019)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines
por: Dessilly, Géraldine, et al.
Publicado: (2014)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

A new method to calculate intra‐patient variability in tacrolimus concentrations
por: van Gelder, Teun
Publicado: (2021)

Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection
por: Sablik, Kasia A., et al.
Publicado: (2018)

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose
por: Andrews, Louise M., et al.
Publicado: (2017)

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
por: Francke, Marith I., et al.
Publicado: (2020)

Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1
por: Degraeve, Alexandra L., et al.
Publicado: (2023)

High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2022)

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
por: Andrews, Louise M., et al.
Publicado: (2017)

CYP3A4(∗)22 Genotyping in Clinical Practice: Ready for Implementation?
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
por: Francke, Marith I., et al.
Publicado: (2021)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
por: Belkhir, Leïla, et al.
Publicado: (2016)

Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms
por: Jeong, Seung-Hyun, et al.
Publicado: (2022)

Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography–tandem mass spectrometry
por: Bahmany, Soma, et al.
Publicado: (2018)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus‐treated transplant recipients?
por: Robertsen, Ida, et al.
Publicado: (2019)

Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity
por: Zhai, Qinglian, et al.
Publicado: (2022)

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
por: Åsberg, Anders, et al.
Publicado: (2013)

The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations
por: Fontova, Pere, et al.
Publicado: (2023)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement
por: Andrews, Louise M., et al.
Publicado: (2019)

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
por: van der Zwan, Marieke, et al.
Publicado: (2017)

A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients
por: Tang, Jiang-Tao, et al.
Publicado: (2018)

Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?
por: in ‘t Veld, Aliede E., et al.
Publicado: (2019)

Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
por: Dessilly, Géraldine, et al.
Publicado: (2016)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients
por: Franken, Linda G., et al.
Publicado: (2022)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
por: Labriffe, Marc, et al.
Publicado: (2022)

Pop in, pop out: a novel gene-targeting strategy for use with CRISPR-Cas9
por: Kühn, Ralf, et al.
Publicado: (2015)

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023)

Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation
por: Crespo, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0g7g2er0uj5d30pgq51ff7e99s